Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NOURA J CHOUDHURY

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1841649332
CMS profile
1454063
Location
CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$8,282.71

9 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $7,225.00 1
Travel and Lodging $930.71 5
Food and Beverage $127.00 3

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
GENZYME CORPORATION $8,282.71 9

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NOURA J CHOUDHURY

NPI 1841649332 · CMS profile ID 1454063

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1841649332?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NOURA J CHOUDHURY, NPI 1841649332, CMS profile ID 1454063. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1841649332?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). NOURA J CHOUDHURY, NPI 1841649332, CMS profile ID 1454063. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1841649332?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
NOURA J CHOUDHURY, NPI 1841649332, CMS profile ID 1454063, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1841649332?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

9 matching records · $8,282.71 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 9 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–9 of 9.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GENZYME CORPORATION $35.0001/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049645695 CMS
GENZYME CORPORATION $115.4101/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049645701 CMS
GENZYME CORPORATION $127.2101/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049645707 CMS
GENZYME CORPORATION $422.3501/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049645711 CMS
GENZYME CORPORATION $7,225.0001/27/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049646101 CMS
GENZYME CORPORATION $230.7401/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049646107 CMS
GENZYME CORPORATION $20.0001/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049646113 CMS
GENZYME CORPORATION $36.0001/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049646121 CMS
GENZYME CORPORATION $71.0001/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049646127 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $194.00 2
PY2022 $15.50 1
PY2023 $8,282.71 9
PY2024 $14,757.57 11
PY2025 $15,377.47 14

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,427.64 2
PY2025 Principal investigator $307,356.67 66
PY2024 Principal investigator $1,388,670.65 463
PY2023 Principal investigator $1,562,080.65 113
PY2022 Principal investigator $223,487.22 11

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

68 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
UCM EMERGENCY DEPARTMENT OUTPATIENT PHARMACY
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination with Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects with Advanced Solid Tumors No dispute reported 06/30/2026 1202534553
Principal investigator 1 ABBVIE INC. $1,347.00 12/24/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202531966
Principal investigator 1 ABBVIE INC. $1,347.00 12/24/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202531968
Principal investigator 1 ABBVIE INC. $2,922.00 12/24/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202531970
Principal investigator 1 ABBVIE INC. $2,922.00 12/24/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202531972
Principal investigator 1 ABBVIE INC. $2,922.00 12/24/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202531974
Principal investigator 1 ABBVIE INC. $1,347.00 12/24/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202531978
Principal investigator 1 ABBVIE INC. $2,922.00 12/24/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202531980
Principal investigator 1 ABBVIE INC. $1,347.00 11/27/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202525976
Principal investigator 1 ABBVIE INC. $1,347.00 11/27/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202525978
Principal investigator 1 ABBVIE INC. $2,922.00 11/27/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202525980
Principal investigator 1 ABBVIE INC. $4,680.00 11/19/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202524608
Principal investigator 1 ABBVIE INC. $3,640.00 11/19/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202524610
Principal investigator 1 ABBVIE INC. $1,347.00 10/29/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202519421
Principal investigator 1 ABBVIE INC. $3,358.00 10/29/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202519423
Principal investigator 1 ABBVIE INC. $2,922.00 10/29/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202519425
Principal investigator 1 ABBVIE INC. $1,347.00 10/29/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202519483
Principal investigator 1 ABBVIE INC. $1,347.00 10/29/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202519485
Principal investigator 1 ABBVIE INC. $1,347.00 10/29/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202519487
Principal investigator 1 ABBVIE INC. $2,922.00 10/29/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202519489
Principal investigator 1 ABBVIE INC. $2,922.00 09/29/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202512562
Principal investigator 1 ABBVIE INC. $1,347.00 09/29/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202512574
Principal investigator 1 ABBVIE INC. $1,347.00 09/29/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202512754
Principal investigator 1 Amgen Inc. $1,279.67 09/20/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy No dispute reported 06/30/2026 1246644527
Principal investigator 1 ABBVIE INC. $1,347.00 09/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202506597
Principal investigator 1 ABBVIE INC. $1,347.00 09/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202506599
Principal investigator 1 ABBVIE INC. $1,347.00 09/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202506601
Principal investigator 1 ABBVIE INC. $2,922.00 09/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202506603
Principal investigator 1 ABBVIE INC. $1,347.00 09/01/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202506639
Principal investigator 1 ABBVIE INC. $1,347.00 08/04/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202500914
Principal investigator 1 ABBVIE INC. $2,922.00 08/04/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202500916
Principal investigator 1 ABBVIE INC. $1,347.00 06/26/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202492937
Principal investigator 1 ABBVIE INC. $1,347.00 06/26/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202492939
Principal investigator 1 ABBVIE INC. $1,347.00 06/26/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202492975
Principal investigator 1 ABBVIE INC. $1,347.00 06/26/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202492977
Recipient ABBVIE INC. $93.00 05/31/2025 Covered Recipient Physician Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202397698
Principal investigator 1 ABBVIE INC. $1,347.00 05/29/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202486633
Principal investigator 1 ABBVIE INC. $2,922.00 05/29/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202486683
Principal investigator 1 ABBVIE INC. $1,347.00 05/29/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202486685
Principal investigator 1 ABBVIE INC. $1,347.00 05/29/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202486687
Principal investigator 1 ABBVIE INC. $2,922.00 05/29/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202486689
Principal investigator 1 ABBVIE INC. $2,275.00 05/28/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202486381
Principal investigator 1 ABBVIE INC. $520.00 05/28/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202486383
Principal investigator 1 ABBVIE INC. $10,400.00 05/28/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202486385
Principal investigator 1 ABBVIE INC. $17,277.43 05/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer No dispute reported 06/30/2026 1202486147
Principal investigator 1 ABBVIE INC. $25,812.70 05/21/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer No dispute reported 06/30/2026 1202485601
Principal investigator 1 ABBVIE INC. $20,282.00 05/01/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer No dispute reported 06/30/2026 1202480683
Principal investigator 1 ABBVIE INC. $1,347.00 04/30/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202479913
Principal investigator 1 ABBVIE INC. $2,922.00 04/30/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202479915
Principal investigator 1 ABBVIE INC. $1,347.00 04/30/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202480057
Principal investigator 1 ABBVIE INC. $1,347.00 04/28/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202479618
Principal investigator 1 ABBVIE INC. $2,532.00 03/26/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202466288
Principal investigator 1 ABBVIE INC. $1,512.00 03/26/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202466293
Principal investigator 1 ABBVIE INC. $1,512.00 03/26/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202466298
Principal investigator 1 ABBVIE INC. $1,214.00 03/26/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202466302
Principal investigator 1 ABBVIE INC. $1,512.00 03/26/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202466323
Principal investigator 1 ABBVIE INC. $1,214.00 03/26/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202466326
Principal investigator 1 ABBVIE INC. $1,512.00 03/26/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202466330
Principal investigator 1 ABBVIE INC. $1,347.00 03/26/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202466334
Principal investigator 1 ABBVIE INC. $1,214.00 03/26/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202466338
Principal investigator 1 ABBVIE INC. $3,182.00 03/26/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202466342
Principal investigator 1 Amgen Inc. $118,965.87 03/22/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Tarlatamab in Subjects With Small Cell Lung Cancer (DeLLphi-300) No dispute reported 06/30/2026 1246644450
Principal investigator 1 ABBVIE INC. $1,347.00 02/27/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202454751
Principal investigator 1 ABBVIE INC. $2,922.00 02/27/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202454755
Principal investigator 1 ABBVIE INC. $1,512.00 02/27/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202454759
Principal investigator 1 ABBVIE INC. $1,214.00 02/27/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202454807
Principal investigator 1 ABBVIE INC. $1,512.00 02/27/2025 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202454810
Recipient Amgen Inc. $2,334.64 02/01/2025 Covered Recipient Physician Practical Management of Adverse Events in Patients Receiving Tarlatamab, a DLL3-targeted Bispecific T-cell Engager Immunotherapy, for Previously Treated Small Cell Lung Cancer No dispute reported 06/30/2026 1246637238